These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 19144684)

  • 21. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
    Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
    Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
    Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
    Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
    Kudo M; Imanaka K; Chida N; Nakachi K; Tak WY; Takayama T; Yoon JH; Hori T; Kumada H; Hayashi N; Kaneko S; Tsubouchi H; Suh DJ; Furuse J; Okusaka T; Tanaka K; Matsui O; Wada M; Yamaguchi I; Ohya T; Meinhardt G; Okita K
    Eur J Cancer; 2011 Sep; 47(14):2117-27. PubMed ID: 21664811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
    Morimoto M; Numata K; Moriya S; Kondo M; Nozaki A; Morioka Y; Maeda S; Tanaka K
    Anticancer Res; 2012 Feb; 32(2):619-23. PubMed ID: 22287754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
    Vitale A; Boccagni P; Kertusha X; Zanus G; D'Amico F; Lodo E; Pastorelli D; Ramirez Morales R; Lombardi G; Senzolo M; Burra P; Cillo U
    Transplant Proc; 2012 Sep; 44(7):1989-91. PubMed ID: 22974889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
    Petrini I; Lencioni M; Ricasoli M; Iannopollo M; Orlandini C; Oliveri F; Bartolozzi C; Ricci S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):773-80. PubMed ID: 22033636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
    Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
    J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
    Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
    Koschny R; Gotthardt D; Koehler C; Jaeger D; Stremmel W; Ganten TM
    Oncology; 2013; 84(1):6-13. PubMed ID: 23075905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
    Frenette CT; Frederick RT; Gish RG
    J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
    J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.